NEW YORK (GenomeWeb) – Enthusiasm for participating in the National Cancer Institute's MATCH trial has been higher than investigators expected, but, according to researchers knowledgeable of the project, the study hasn't yet "matched" many patients to treatments based on the genomic markers driving their disease.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.